RESUMO
Since the arrival of COVID-19, tourism scholarship has focused its attention on rethinking and restarting the tourism sector. In this urgent search for a 'new normal', the embodied experience of hosting such an unwelcomed virus, the philosophical questions this raises, and the tourism futures already in the making, have not been fully explored. The article introduces Nancy's (2000/2002) philosophy, L'intrus [The Intruder], where he reflects on having a heart transplant operation to give body to the experiences of the self as exteriority and of otherness always already within. We take inspiration from Nancy to think and sense the experience of the COVID-19 virus intrusion in tourism. To do this, we weave personal philosophical reflections with ethnographic material to reflect on three themes of intrusion for tourism scholarship to consider: the experience of a body/self as exposed, the experience of a shattered self, and the experience of uncertain futures.
RESUMO
BACKGROUND: Cellular therapies have shown encouraging results in the treatment of chronic osteoarthritis (OA). Herein, we present the final results of a phase I-II clinical trial assessing the feasibility, safety and efficacy of ex vivo expanded autologous bone marrow Mesenchymal Stromal Cells (MSC, XCEL-M-ALPHA), infused intra-articularly, in patients with knee OA. METHODS: Fifteen patients (median age=52years) with grade II(9) or III(6) gonarthrosis (Kellgren & Lawrence classification) and chronic pain were treated with an intra-articular infusion of 40.9×10(6)±0.4×10(6) MSCin a phase I-II prospective, open-label, single-dose, single-arm clinical trial. Endpoints were safety and tolerability. Efficacy was measured by the Visual Analogue Scale for pain, algofunctional Health Assessment Questionnaire, Quality of Life (QoL) SF-36 questionnaire, Lequesne functional index and WOMAC score. Cartilage integrity was assessed by Magnetic Resonance Imaging and quantitative T2-mapping at 0, 6 and 12months. RESULTS: The cell-based product was well tolerated with few reported Adverse Events (mild arthralgia and low back pain). There was a relevant decrease in the intensity of pain since day 8 after the infusion, that was maintained after 12months. The SF-36 QoL test showed improvement of parameters including bodily pain, role physical and physical functioning at month 12. The health assessment questionnaire revealed a significant decrease of incapacity. Moreover, T2 mapping showed signs of cartilage regeneration in all patients at 12months post-treatment. CONCLUSIONS: Single intra-articular infusion of XCEL-M-ALPHA is a safe and well-tolerated cell-based product, associated with a long-lasting amelioration of pain, improvement of QoL (up to four years), and signs of cartilage repair.
